NFKB1 and neoplasm: It decreased tumor growth in vivo via activating the NF-κB signaling pathway and binding to the promoter region of PSA, as well as reducing the expression of angiogenesis and inflammation-related genes (Gueron et al., 2009; Ferrando et al., 2011; Elguero et al., 2012).